TD Waterhouse Canada’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

TD Waterhouse Canada’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-850	Closed	-$211	–	1805
2022 Q3	$211	Hold	850	–	–	﹤0.01%	1657
2022 Q2	$693	Hold	850	–	–	﹤0.01%	1648
2022 Q1	$1.29K	Hold	850	–	–	﹤0.01%	1644
2021 Q4	$2.76K	Buy	+850	New	+$2.57K	﹤0.01%	1542

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TD Waterhouse Canada's PHAS Position: Q4 2022 in Review

TD Waterhouse Canada sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 850 shares — an estimated $211 sold.

TD Waterhouse Canada first reported a position in PHAS in Q4 2021 and held it in 4 quarters. The position peaked at $2.76K in Q4 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

TD Waterhouse Canada reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
TD Waterhouse Canada sold 850 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $211.
TD Waterhouse Canada first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
TD Waterhouse Canada's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $2.76K in Q4 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on TD Waterhouse Canada's 13F filing for Q4 2022, filed 13 Nov 2023.